Farah Champsi, Director at Kite Pharma, Inc. (KITE), sold 247,626 shares at $82.34 ($20.5M) on 2017-04-24, disclosed to the SEC on 2017-04-26.
Open-market sale of $20.5M KITE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.34 | 25,818 | $2.1M | 10.4% |
| 2 | $82.34 | 25,818 | $2.1M | 10.4% |
| 3 | $82.56 | 31,467 | $2.6M | 12.7% |
| 4 | $82.56 | 31,467 | $2.6M | 12.7% |
| 5 | $83.29 | 15,316 | $1.3M | 6.2% |
| 6 | $83.29 | 15,316 |
| $1.3M |
| 6.2% |
| 7 | $82.72 | 51,112 | $4.2M | 20.7% |
| 8 | $82.72 | 51,112 | $4.2M | 20.7% |
| 9 | $83.06 | 200 | $17K | 0.1% |
| Total | $82.67 avg | 247,626 | $20.5M | 100% |
| Filing → |
| KITE | SELL | 2017-04-17 | $19.0M | — | Filing → |
| KITE | SELL | 2015-07-02 | $41.4M | — | Filing → |
| CMRX | SELL | 2013-10-23 | $6.9M | — | Filing → |